Vorapaxar

BreastfeedingPediatric
  • TRADE NAME: Zontivity (Merck)
  • INDICATIONS: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease
  • CLASS: Protease-activated receptor-1 (PAR-1) antagonist
  • HALF-LIFE: 3–4 days

FDA APPROVAL DATE: 05/08/2014

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Boceprevir, Carbamazepine, Clarithromycin, Conivaptan, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inhibitors or inducers, Telaprevir, Telithromycin

PREGNANCY CATEGORY: B

Contra-indicated in patients with a history of stroke, transient ischemic attack, or intracranial hemorrhage, or with active pathological bleeding.

BLEEDING RISK

See full prescribing information for complete boxed warning.

Our database has 14 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
OCULAR.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top